Is Proflavine Exposure Associated with Disease Progression in Women with Cervical Dysplasia? A Brief Report

Simple item page
dc.citation.firstpage1308
dc.citation.issueNumber6
dc.citation.journalTitlePhotochemistry and Photobiology
dc.citation.lastpage1313
dc.citation.volumeNumber94
dc.contributor.authorPantano, Naitielle
dc.contributor.authorHunt, Brady
dc.contributor.authorSchwarz, Richard A.
dc.contributor.authorParra, Sonia
dc.contributor.authorCherry, Katelin
dc.contributor.authorPossati‐Resende, Júlio César
dc.contributor.authorLongatto‐Filho, Adhemar
dc.contributor.authorFregnani, José Humberto Tavares Guerreiro
dc.contributor.authorCastle, Philip E.
dc.contributor.authorSchmeler, Kathleen
dc.contributor.authorRichards‐Kortum, Rebecca
dc.date.accessioned2019-01-09T17:21:10Z
dc.date.available2019-01-09T17:21:10Z
dc.date.issued2018
dc.description.abstractProflavine is an acridine dye used with high-resolution microendoscopy for in vivo diagnostic evaluation of cervical epithelial cells. However, there are concerns that even short-term exposure of cervical tissue to dilute proflavine may increase cervical cancer risk. We performed a retrospective analysis of women referred for colposcopy to Barretos Cancer Hospital comparing the risk of cervical disease progression in those whose cervical tissue was (n = 232) or was not exposed (n = 160) to proflavine. Patients in both groups underwent treatment and follow-up based on histopathologic results and per the local standards of care. Progression of disease was evaluated by comparing histopathology from the initial visit to the worst subsequent histopathology result from all follow-up visits. Mean duration of follow-up was 18.7 and 20.1 months for the proflavine-exposed and controls groups, respectively. There were no significant differences in disease progression from normal/CIN1 to CIN2/3 or from any initial diagnosis to invasive cancer between the proflavine exposed and control groups overall. Risks of cervical dysplasia progression observed in this study are in agreement with those of the natural history of cervical cancer. Our results suggest that cervical exposure to dilute proflavine does not increase the risk of cervical precancer and cancer.
dc.identifier.citationPantano, Naitielle, Hunt, Brady, Schwarz, Richard A., et al.. "Is Proflavine Exposure Associated with Disease Progression in Women with Cervical Dysplasia? A Brief Report." <i>Photochemistry and Photobiology,</i> 94, no. 6 (2018) Wiley: 1308-1313. https://doi.org/10.1111/php.12976.
dc.identifier.digitalProflavine-Exposure
dc.identifier.doihttps://doi.org/10.1111/php.12976
dc.identifier.urihttps://hdl.handle.net/1911/105024
dc.language.isoeng
dc.publisherWiley
dc.rightsThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleIs Proflavine Exposure Associated with Disease Progression in Women with Cervical Dysplasia? A Brief Report
dc.typeJournal article
dc.type.dcmiText
dc.type.publicationpublisher version
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Proflavine-Exposure.pdf
Size:
418.9 KB
Format:
Adobe Portable Document Format
Download
Collections
Faculty Publications
Bioengineering Publications